Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
KEYNOTE-355随机研究结果显示,帕博利珠单抗联合化疗治疗亚洲晚期三阴性乳腺癌患者疗效不佳。
期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-024-00679-7
Im, Seock-Ah; Cortes, Javier; Cescon, David W; Yusof, Mastura Md; Iwata, Hiroji; Masuda, Norikazu; Takano, Toshimi; Huang, Chiun-Sheng; Chung, Chi-Feng; Tsugawa, Koichiro; Park, Yeon Hee; Matsumoto, Koji; Inoue, Kenichi; Kwong, Ava; Loi, Sherene; Fu, Wei; Pan, Wilbur; Karantza, Vassiliki; Rugo, Hope S; Schmid, Peter